Podcast: Download (Duration: 15:21 — 12.0MB) | Embed
Subscribe: Spotify | Email | TuneIn | RSS | More
Jeff Robinson, CEO of Wuhan General Group, Inc., (the “Company”) called in to SmallCapVoice.com to go over the business model and markets for his exciting young Company. Jeff talked about the the launching of its premium CBD product lines. The launch includes the CBD cosmetics line and the CBD coffee line in pharmacies, convenience stores and hotels across South Africa. The products are branded under the trademarks: DrAnnaRx™ and Medspresso™ respectively. He went on to talk about the Company’s work with its newly established division, M2Bio who is researching and developing indications for psilocybin new therapies that will help patients who suffer from mental illness, Alzheimer’s and Parkinson’s.
Wuhan General Group, Inc. through its wholly-owned subsidiary MJ MedTech is a nutraceutical biotechnology company that researches, develops and commercializes a range of CBD-based products under the Dr. AnnaRx™ and Medspresso™ brands. In addition, its new wholly-owned division, M2Bio is researching and developing indications for psilocybin new therapies that will help patients who suffer from mental illness, Alzheimer’s and Parkinson’s. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research and emerging technologies. Wuhan is listed and traded on the Over the Counter Bulletin Board of NASDAQ under the trading symbol “WUHN”.
